key: cord-0800385-n7qtdi2u
authors: Ghoshal, Uday C
title: Postinfection Irritable Bowel Syndrome
date: 2022-05-15
journal: Gut Liver
DOI: 10.5009/gnl210208
sha: 0a21d47aa0f56652b047fe03938a49913375ea8b
doc_id: 800385
cord_uid: n7qtdi2u

Following acute gastroenteritis (AGE) due to bacteria, viruses, or protozoa, a subset of patients develop new onset Rome criteria positive irritable bowel syndrome (IBS), called postinfection IBS (PI-IBS). The pooled prevalence of PI-IBS following AGE was 11.5%. PI-IBS is the best natural model that suggests that a subset of patients with IBS may have an organic basis. Several factors are associated with a greater risk of development of PI-IBS following AGE including female sex, younger age, smoking, severity of AGE, abdominal pain, bleeding per rectum, treatment with antibiotics, anxiety, depression, somatization, neuroticism, recent adverse life events, hypochondriasis, extroversion, negative illness beliefs, history of stress, sleep disturbance, and family history of functional gastrointestinal disorders (FGIDs), currently called disorder of gut-brain interaction. Most patients with PI-IBS present with either diarrhea-predominant IBS or the mixed subtype of IBS, and overlap with other FGIDs, such as functional dyspepsia is common. The drugs used to treat non-constipation IBS may also be useful in PI-IBS treatment. Since randomized controlled trials on the efficacy of drugs to treat PI-IBS are rare, more studies are needed on this issue.

Functional gastrointestinal disorders (FGIDs), including irritable bowel syndrome (IBS), are common conditions globally, both in the community and in clinical practice. 1 IBS is associated with significant impairment in quality of life, work productivity, psychological comorbidity, health-care utilization, and economic consequences. 2 The pathogenesis of IBS is enigmatic. 3 There has been a paradigm shift recently on the pathogenesis of IBS from psychosomatic disorder to micro-organic condition. 3 The Rome Foundation experts recognize this in the Rome IV criteria for IBS published in 2016 in which IBS has been considered to be a disorder of "gut-brain interaction" rather than "brain-gut interaction. " 4 Of the several pieces of evidence behind considering IBS to be a micro-organic disorder, the development of the condition following an infectious illness, called postinfection IBS (PI-IBS), is the most important one. 3, 5, 6 PI-IBS is diagnosed when new onset Rome-criteria positive IBS develops in an individual after acute gastroen-teritis (AGE) characterized by one or more of the following features, (1) diarrhea, (2) vomiting, (3) fever, and (4) a positive stool culture. 6 However, these criteria may need to be modified considering the suggestion that the patients with coronavirus disease-19 (COVID-19), which may not always be associated with diarrhea, may also develop PI-IBS. [7] [8] [9] The pathogenesis of PI-IBS is multifactorial, including the agent, host, and host-agent interaction-related factors. 10 The current manuscript plans to review the (1) epidemiology, including risk factors, (2) etiology and pathogenesis, (3) clinical presentation, (4) investigations, (5) management, and (6) prognosis of PI-IBS. It also summarizes the future direction on the subject. than the development of IBS among the control population in 16 studies (0.3% to 23.3%). 10 In a recent meta-analysis, the pooled prevalence of PI-IBS was 11.5% (2,217/21,421; 95% confidence interval, 8.2 to 15.8); the prevalence was comparable in the studies reporting prevalence at 3, 6, 12, 13-59, or ≥60 months after AGE. 40 Wide variations in PI-IBS prevalence in different studies are related, at least in part, to the difference in the frequency of various risk factors for PI-IBS development in the diverse patient population.

Multiple factors have been identified to be associated with a greater risk of developing PI-IBS following AGE. The risk factors for the development of PI-IBS include female sex, younger age, smoking, severity of AGE (including stool frequency and diarrhea duration longer than 1 week), abdominal pain, bleeding per rectum, treatment with antibiotics, anxiety, depression, somatization, neuroticism, recent adverse life events, hypochondriasis, extroversion, negative illness beliefs, history of stress, sleep disturbance, and family history of FGIDs. 10, 33, 40 In one of our studies, we found that the patients who continued to have lower and upper gastrointestinal (GI) symptoms referred to as chronic bowel dysfunction and dyspeptic symptoms during the initial period of follow-up after AGE were more likely to develop IBS and functional dyspepsia after the 6-month cutoff time point, which is required to diagnose these conditions as per the Rome criteria. 32, 41 In a Canadian study on PI-IBS, the authors developed and validated a risk score. 42 For the risk score development, the authors used the risk factors mentioned above, including the demographic and psychological parameters and AGE-related parameters. In addition, they used weight loss of at least 10 lbs (4.5 kg) as one of the parameters. The authors found that if the score was low (score <42), 10% developed PI-IBS. In the intermediate and high (>69) score groups, 35% and 60% of AGE patients developed PI-IBS, respectively. 42 This scoring system was validated in an Indian cohort, which showed that with a cutoff value of >50, the sensitivity and specificity of the score to predict the development of PI-IBS at 6-month follow-up were 91.4% and 84.2%, respectively. 33 Since the different cohorts of AGE patients reported are pretty heterogeneous concerning the above risk factors and the types of the organism causing the gastroenteritis episodes, the wide variation in the prevalence of PI-IBS ranging from 3.7% to 85.5% following AGE is not unexpected. 10 ETIOLOGY AND PATHOGENESIS

As shown in Table 1 , infection with bacterial, viral, and protozoal agents causing AGE has been reported to be followed by PI-IBS. Among bacteria, infection with organisms causing dysentery such as Shigella is more likely to result in PI-IBS than others. 10 However, recently, even bacterial pathogens that conventionally do not invade the gut mucosa, such as Vibrio cholerae are also shown to cause PI-IBS. 32, 33 Protozoal agents such as Giardia lamblia have been associated with PI-IBS development with a high frequency. 10, 40 However, it is essential to mention that most PI-IBS studies following protozoal infection have been reported from two countries: Norway and Turkey. 6, 10 In some of these studies, a negative result on stool microscopy during follow-up was considered to denote eradication of giardiasis. 26, 29 However, it is well-known that the properly performed stool microscopy detect Giardia only in two-thirds of patients. 43 Hence, some of these patients diagnosed with PI-IBS following Giardia infection might be suffering from chronic giardiasis. Since chronic giardiasis is known to cause malabsorption syndrome and chronic diarrhea, 44 and PI-IBS is often diarrhea-predominant type, there might be diagnostic confusion between chronic giardiasis and PI-IBS. More adequately designed studies are needed on this issue.

PI-IBS less commonly follows viral diarrhea. As shown in Table 2 , in the four case-control studies on PI-IBS following viral diarrhea, 0.4% to 12.5% of patients following viral diarrhea developed PI-IBS; 24, 27, 45, 46 however, the frequency among viral diarrhea patients was greater than that among the controls. The low frequency of PI-IBS in patients with viral diarrhea is expected; viral agents causing 7 This is not entirely unexpected as angiotensin-converting enzyme-2 (ACE-2) receptors, the binding site of SARS-CoV-2, are also present in intestinal epithelial cells; the virus has been detected in feces in about half of the patients, GI symptoms, including diarrhea occur in about one-fifth of patients, fecal calprotectin, a marker of GI inflammation, and mucosal serotonin are raised in patients with COVID-19, macroscopic as well as histological evidence of GI mucosal injury occur in them, and gut microbiota dysbiosis has been shown to occur in patients with COVID-19. 7-9,47-55 Moreover, the SARS-CoV-2 virus has an affinity to involve central and peripheral nervous systems as evidenced by anosmia and ageusia occurrence in 15% to 30% of patients and autopsy findings of marked inflammation of olfactory bulb, cere-brum, and brainstem. 53, 54 Patients with COVID-19 have also been shown to increased intestinal permeability. 56 Moreover, the psychological stress due to the COVID-19 pandemic may be associated with central hypervigilance. 55 Fig. 1 summarizes all these putative pathophysiological mechanisms, which may be related to the development of post-COVID-19 FGIDs. Though based on these potential pathophysiological mechanisms, we hypothesized on a possibility of an inevitable surge of post-COVID-19 FGIDs; 7 it is yet to be proved by a published study.

The pathogenesis of PI-IBS involves agent, host, and host-agent interaction-related factors. As shown in Tables 1 and 2, the reported frequency of PI-IBS development is highest with protozoa, intermediate with bacteria, and lowest with the viral agents. 10 Several host factors interplay with the infectious agent leading to protracted long-term inflammation of the gut, which might be compounded by inadequate T regulatory responses controlling the inflammation. 10 Chronic inflammation and altered intestinal permeability have been shown in patients with diarrheapredominant IBS (IBS-D), including PI-IBS. 10, 57 In a casecontrol study in a cohort of 21 AGE patients due to Campylobacter and 12 controls, enteroendocrine cells, CD3, CD4, and CD8 lymphocyte counts in lamina propria and intraepithelial lymphocytes and small intestinal permeability were increased in PI-IBS patients than the controls. 58 In a recent systematic review and meta-analysis, small intestinal permeability was more often abnormal among patients with PI-IBS (4/4 studies) and IBS-D (9/13 studies) than those with constipation-predominant IBS (IBS-C; 2/7 studies). 59 Lack of down-regulation in the inflammatory response following acute GI infection contributes to the development of PI-IBS. In a study on eight PI-IBS patients, seven with AGE not developing PI-IBS and 18 healthy controls, the patients with PI-IBS exhibited increased inflammatory cell infiltrate and higher levels of interleukin (IL)-1β (a pro-inflammatory cytokine) mRNA in rectal biopsies by reverse transcriptase-polymerase chain reaction even 3 months after AGE compared to the other groups. 60 PI-IBS patients have also been shown to have increased levels of peripheral IL-6, pleiotropic cytokine activating inflammatory nuclear factor (NF)-kB transcription pathway, compared to the healthy controls. 61, 62 Host factors are essential determinant of the protracted inflammatory response following GI infection. Polymorphisms in several pro-and anti-inflammatory cytokine genes increasing and decreasing their responses, respectively, have been shown to play an important role. The Canadian Walkerton cohort polymorphism study revealed a trend towards an association between single nucleotide polymorphisms in the gene involved in the immune and gut epithelial barrier pathways located in TLR9 (encoding pattern recognition receptor [rs352139 and P545P]) and CDH1 (encoding a tight junction protein [rs16260, -C160A], and IL-6 (rs1800795, -G174C) and development of PI-IBS. 63 In another study, TNF alpha polymorphism was associated with PI-IBS following Campylobacter jejuni infection. 64 We found that patients with IBS-D and PI-IBS had higher rectal mucosal serotonin and polymorphism in the serotonin re-uptake protein gene than controls. 65 Gut microbiota dysbiosis is another crucial contributor to the development of PI-IBS. Gut microbiota gets altered during the acute phase in patients with AGE 66 that may last long after the AGE episode. 67 PI-IBS patients have been shown to have unique gut microbiota signature compared to the other IBS patients. 68 De Palma et al. 69 successfully colonized mice with fecal microbiota either from IBS-D patients or healthy subjects; the mice receiving microbiota from IBS-D patients as opposed to those receiving from healthy subjects developed IBS phenotypes such as altera-tion in gut transit, anxiety-like behavior, abnormal intestinal permeability, higher CD3 positive cells in intestinal crypts, C3, CXR3, NF-kB, and β defensin. Gut microbiota in patients with IBS has been shown to have reduced diversity akin to patients with non-PI-IBS. 67 Relatively greater abundances of microbes of Bacteroidetes phylum (including Bacteroides and Prevotella) and a relative reduction in those of the phylum Firmicutes such as Clostridia are shown in patients with PI-IBS than controls. 62 However, more data are needed to evaluate whether such alterations in the gut microbiota are the causes or effects of AGE and PI-IBS; these patients might have modified their diet, received antibiotics, and altered gut motility, which are known to alter the gut microbiota. [70] [71] [72] However, since gut microbiota influences gut motility, visceral hypersensitivity, immune response, psychological dysfunction, sleep disturbances, serotonin, and bile acid metabolism, which are associated with FGIDs, including IBS, the role of gut microbiota dysbiosis in the pathogenesis of PI-IBS cannot be over-estimated. [70] [71] [72] 

The criteria laid down by the Rome Foundation Working Team on PI-IBS suggest that this condition should be diagnosed when new onset Rome-criteria positive IBS develops in an individual after AGE characterized by two or more of the following features; diarrhea, vomiting, and fever (when stool culture is not available). 6 However, it is essential to note that though the Rome Foundation Working Team on PI-IBS suggested using Rome IV criteria for diagnosis of PI-IBS, considering the low sensitivity of Rome IV criteria compared to the Rome III criteria to diagnose IBS, 1,73 the latter criteria may also be acceptable.

As Rome criteria require that the symptoms must have started at least 6-month before and the patients must be symptomatic during the last 3 months, many patients continuing to fulfill the Rome criteria for IBS following AGE would not be diagnosed as IBS unless they wait for 6 months to meet the criteria. 4, 6, 41 Hence, we proposed that if the symptoms of IBS are present during the follow-up after AGE, but the subjects did not fulfill the duration criteria suggested by the Rome Foundation, the condition be called chronic bowel dysfunction, 32 which the Rome Foundation Working Team has accepted. 6 An essential clinical clue to the possibility of PI-IBS comes from the targeted question to the patients "When did the symptom start?" If the patient recalls the date or month, the clinicians should be alert about the possibility of PI-IBS. Most patients with PI-IBS have either IBS-D or mixed type of IBS. 40 PI-IBS may have other overlapping FGIDs. In one of our earlier studies, of 66 of 345 AGE patients developing PI-FGIDs, 16 (24%) had overlapping functional dyspepsia. 32 Patients may also have other extra-GI symptoms such as psychological comorbidity, sleep dysfunction similar to the other non-PI-IBS.

The investigations in patients with PI-IBS include routine hematology, blood biochemistry, C-reactive protein, fecal calprotectin, and stool microscopy to look for protozoa, such as Giardia. 6 However, it is essential to mention that in the presence of severe symptoms, significant weight loss, anorexia, local epidemiology, and the other clinical clues (based even on the results of the initial tests), investigations to rule out other causes of chronic diarrhea such as celiac disease, tropical sprue, microscopic and collagenous colitis, and inflammatory bowel disease are warranted. 6 Since about one-tenth of patients with Rome-criteria defined, PI-IBS may have post-infectious malabsorption syndrome (tropical sprue) in tropical countries and visitors to these endemic regions, the investigations for tropical sprue should be undertaken if clinically indicated. 32 PI-IBS and tropical sprue are spectrum disorders. The investigations for tropical sprue include D-xylose test, fecal fat excretion, serum vitamin B 12 estimation, and endoscopic duodenal biopsy. 32 Since a third of patients with tropical sprue and about a fifth of patients with IBS-D have small intestinal bacterial overgrowth (SIBO), a glucose hydrogen breath test may be done as a specialized investigation to diagnose SIBO in patients with PI-IBS. 74 Fig. 2 . Potentially useful drugs in the treatment of PI-IBS. In the light green box, the drugs that have been evaluated in RCTs are listed (filled green circles indicate the drugs that were found to be effective in the RCTs, and empty red circles show those that were found to be ineffective). The pink box lists the drugs that were found to be effective in diarrhea-predominant IBS but have not yet been evaluated in PI-IBS. 5-ASA, 5-aminosalicylic acid; RCT, randomized controlled trial; IBS, irritable bowel syndrome; IBS-D, diarrhea-predominant IBS; PI-IBS, postinfection IBS. Hence, these may be helpful in diagnosis in selected patients.

The data on the treatment of PI-IBS are scanty. Hence, currently, these patients are treated in the same way as any IBS-D patient. 6, 78 Fig. 2 outlines the drugs which have been found useful or not in the treatment of PI-IBS and the drugs that have been established in the treatment of IBS-D but have not been evaluated for PI-IBS. 6, 78 The name of drugs for the treatment of IBS-D and their dosages are summarized in Table 3 . Though 5-aminosalicylic acid was not found useful in IBS-D in randomized controlled trials, it benefited the subset of patients with PI-IBS. 79 In a randomized controlled trial from China, dietary glutamine was found useful in PI-IBS patients. 80 Prednisolone and rifaximin were not found useful in PI-IBS. [81] [82] [83] However, the rifaximin study had several limitations, such as a small sample size, low dose of rifaximin (550 mg twice daily), and use of early peak-criteria on lactulose hydrogen breath test for diagnosis of SIBO, which is known to have poor specificity. 82 Since restriction of fermentable oligodi-mono-saccharide and polyol (FODMAP) diet has been shown helpful in IBS, it is also expected to help patients with PI-IBS. 3, 78, 84 However, there is no study yet on the low FODMAP diet in the management of PI-IBS. Visceral neuromodulators, particularly the tricyclic anti-depressants, are expected to be helpful in the management of PI-IBS as these tend to reduce diarrhea by their anticholinergic activity. 3, 78 However, no study has been conducted on this issue in patients with PI-IBS. Since other subtypes of IBS such as mixed IBS and even rarely constipation-predominant IBS may occur after AGE, the management of different subtypes of IBS may also be applicable in patients with PI-IBS. 3, 78 The studies showed that the prognosis of PI-IBS patients is generally good as almost half of them recover during the long-term follow-up. 85, 86 A Korean study showed that though the rates of IBS increased till 3-year, it reduced thereafter. Among the PI-IBS patients, post-viral PI-IBS is more often transient than post-bacterial IBS. 87

PI-IBS is a disorder of gut-brain interaction (previously called FGID), which undoubtedly proved that some patients with FGIDs are not entirely functional. 3,4 PI-IBS may occur following bacterial, protozoal, and viral AGE. 10 Two recent studies, one from Bangladesh and the other from India showed that cholera may be followed by the development of PI-IBS. 32, 33 A pooled prevalence of PI-IBS was 11.5% after an episode of AGE. 40 Most patients with PI-IBS either present as IBS-D or mixed subtype of IBS. 40 Overlap of PI-IBS with other FGIDs, mainly, functional dyspepsia is common. 32 One-fifth of patients with Rome criteria positive PI-IBS may have PI-malabsorption, popularly known as tropical sprue. 32 It is believed that the development of PI-IBS may follow COVID-19. 7 However, studies are urgently needed to evaluate the frequency, spectrum, and risk factors for the development of PI-IBS, if any, following COVID-19. Since most patients with PI-IBS presents with the non-constipation type of IBS, the drugs used to treat non-constipation IBS may also be useful in PI-IBS treatment. However, most of these drugs have not been evaluated for the treatment of IBS. Of the four drugs evaluated by randomized controlled trial, prednisolone and rifaximin were found ineffective in PI-IBS treatment. [81] [82] [83] Dietary glutamine was found useful in the treatment of PI-IBS in a Chinese study. 80 5-Aminosalicylic acid undergoing randomized controlled trial was not found useful in IBS-D patients. 79 However, in the subgroup of patients with PI-IBS, 5-aminosalicylic acid was found useful in IBS-D patients. 79 More studies are needed to evaluate the efficacy of various drugs in the treatment of PI-IBS.

No potential conflict of interest relevant to this article was reported.

Uday C Ghoshal https://orcid.org/0000-0003-0221-8495

Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study

Irritable bowel syndrome in Asia: pathogenesis, natural history, epidemiology, and management

Lecture 2019: a paradigm shift in pathophysiological basis of irritable bowel syndrome and its implication on treatment

Rome IV-functional GI disorders: disorders of gut-brain interaction

The intestinal microenvironment and functional gastrointestinal disorders

Rome Foundation Working Team report on post-infection irritable bowel syndrome

Managing the inevitable surge of post-COVID-19 functional gastrointestinal disorders

Gastrointestinal and hepatic manifestations of corona virus disease-19 and their relationship to severe clinical course: a systematic review and meta-analysis

The spectrum of gastrointestinal symptoms in patients with coronavirus disease-19: predictors, relationship with disease severity, and outcome

Post-infection irritable bowel syndrome in the tropical and subtropical regions: Vibrio cholerae is a new cause of this well-known condition

Irritable bowel syndrome: post salmonella infection

Psychometric scores and persistence of irritable bowel after infectious diarrhoea

The role of psychological and biological factors in postinfective gut dysfunction

Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients

Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study

Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study

Post-traveler's diarrhea irritable bowel syndrome: a prospective study

Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS

Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study

The development of irritable bowel syndrome after Shigella infection: 3 year followup study

Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery

The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection

Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study

Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen

The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis

Development of functional gastrointestinal disorders after Giardia lamblia infection

Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak

Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood

The relationship between irritable bowel syndrome, functional dyspepsia, chronic fatigue and overactive bladder syndrome: a controlled study 6 years after acute gastrointestinal infection

High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection

Post-infectious irritable bowel syndrome (PI-IBS) after infection with Shigalike toxin-producing Escherichia coli (STEC) O104:H4: a cohort study with prospective follow-up

Long-term gastrointestinal consequences are frequent following sporadic acute infectious diarrhea in a tropical country: a prospective cohort study

A prospective study on incidence, risk factors, and validation of a risk score for postinfection irritable bowel syndrome in coastal eastern India

Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis

Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico

Post-infectious irritable bowel syndrome in patients with Shigella infection

Factors associated with the development of post-infectious functional gastrointestinal diseases: does smoking play a role?

Giardia lamblia infection increases risk of chronic gastrointestinal disorders

Post-infectious irritable bowel syndrome after a laboratory-proven enteritis

Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis

Bowel disorders

Development and validation of a risk score for postinfectious irritable bowel syndrome

Role of polymerase chain reaction in stool and duodenal biopsy for diagnosis of giardiasis in patients with persistent/chronic diarrhea

Spectrum of malabsorption syndrome among adults & factors differentiating celiac disease & tropical malabsorption

Postinfectious gastrointestinal disorders following norovirus outbreaks

Rotavirus gastroenteritis: precursor of functional gastrointestinal disorders?

Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus

Detection of SARS-CoV-2 RNA in fecal specimens of patients with confirmed COVID-19: a meta-analysis

Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19

Alterations in gut microbiota of patients with COVID-19 during time of hospitalization

Faecal calprotectin indicates intestinal inflammation in COVID-19

Serotonin is elevated in COVID-19-associated diarrhoea

Infection mechanism of SARS-COV-2 and its implication on the nervous system

Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study

Mental distress among U.S. adults during the COVID-19 pandemic

Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: a working hypothesis

Post-infectious irritable bowel syndrome: the past, the present and the future

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review

Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome

Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome

Postinfection irritable bowel syndrome: the links between gastroenteritis, inflammation, the microbiome, and functional disease

Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis

Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFα

Serotonin transporter gene (SLC6A4) polymorphism in patients with irritable bowel syndrome and healthy controls

Alterations in human intestinal microflora during experimental diarrhoea

Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress

Microbial signatures in post-infectious irritable bowel syndrome: toward patient stratification for improved diagnostics and treatment

Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice

The gut microbiota and irritable bowel syndrome: friend or foe?

Small intestinal bacterial overgrowth and other intestinal disorders

Gut microbiota dysbiosis in functional gastrointestinal disorders: underpinning the symptoms and pathophysiology

Prevalence, overlap, and risk factors for Rome IV functional gastrointestinal disorders among college students in northern India

Tropical sprue is associated with contamination of small bowel with aerobic bacteria and reversible prolongation of orocecal transit time

Post-infectious IBS, tropical sprue and small intestinal bacterial overgrowth: the missing link

A meta-analysis on small intestinal bacterial overgrowth in patients with different subtypes of irritable bowel syndrome

Assessment of antivinculin and anti-cytolethal distending toxin B antibodies in subtypes of irritable bowel syndrome

Pros and cons while looking through an Asian window on the Rome IV criteria for irritable bowel syndrome: pros

A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D)

Randomised placebocontrolled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome

Randomized, doubleblind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome

Rifaximin for irritable bowel syndrome (IBS) in Gulf War veterans: losing the battle but winning the war?

Double-blind placebo-controlled study of rifaximin and lactulose hydrogen breath test in Gulf War veterans with irritable bowel syndrome

All that a physician should know about FODMAPs

Prognosis in post-infective irritable bowel syndrome: a six year follow up study

The clinical course of postinfectious irritable bowel syndrome: a five-year followup study

Post-infectious irritable bowel syndrome